ReviewFrontiers in immunology2026
Beyond density: mapping the functional landscapes of macrophage-T lymphocyte niches in the tumor microenvironment.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spatial arrangement of tumor-associated macrophages (TAMs) and T cells within distinct microanatomical niches is emerging as a key regulator of clinical outcome in solid tumors. Here, we propose a comprehensive review that integrates spatial insights with functional studies of macrophage and T cell heterogeneity, to elucidate how the physical crosstalk and the localization of these cells in the tumor microenvironment (TME) can impact the prognosis and the response to immunotherapy and, vice versa, how diverse immunotherapies can dynamically reshape the TME immune geography. We first review the heterogeneity of macrophages and tumor-infiltrating T lymphocytes (TILs) in TME, and the different types of TAM-TIL niches recently described by multidimensional proteomics and spatial transcriptomics, addressing their impact on tumor progression and response to immunotherapy. Building on our own work, we then dissect the anti-tumoral and pro-tumoral mechanisms operating in the different types of immune hubs. Next, we examine how tumor cues and therapeutic strategies can reprogram macrophages and T cells across functional and spatial dimensions, thereby promoting TME permissive to intraepithelial T cell infiltration and clinical response. Finally, we discuss how the integration of multi-omics and artificial intelligence are transitioning immuno-oncology from a cell-centric to a niche-centric paradigm, providing a roadmap for the design of next-generation therapies that precisely reprogram cellular dialogues within the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.